BRIAN GILBERT to Respiratory Syncytial Virus, Human
This is a "connection" page, showing publications BRIAN GILBERT has written about Respiratory Syncytial Virus, Human.
Connection Strength
1.739
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
Score: 0.464
-
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
Score: 0.312
-
In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections. Virology. 2023 09; 586:115-121.
Score: 0.161
-
Adult Memory T Cell Responses to the Respiratory Syncytial Virus Fusion Protein During a Single RSV Season (2018-2019). Front Immunol. 2022; 13:823652.
Score: 0.147
-
Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein. Vaccine. 2022 01 24; 40(3):536-543.
Score: 0.144
-
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun. 2016 12 21; 7:13916.
Score: 0.102
-
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
Score: 0.099
-
GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1264-73.
Score: 0.095
-
Benzimidazole analogs inhibit respiratory syncytial virus G protein function. Antiviral Res. 2015 Sep; 121:31-8.
Score: 0.092
-
Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med. 2014 Nov; 6(11):1436-54.
Score: 0.088
-
A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas. Vaccine. 2021 02 22; 39(8):1248-1256.
Score: 0.034